Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT027 for Recurrent or Progressive High-Grade Glioma
NCT06737146Phase 1Not yet recruiting
- Sponsor
- Suzhou Maximum Bio-tech
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MT027 CAR-T cells in glioma, sponsored by Suzhou Maximum Bio-tech. Primary endpoints: Adverse Events (AE) and Serious Adverse Events (SAE), Dose Limiting Toxicity at 28 days and 3 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
MT027 CAR-T cells
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06737146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06737146.